Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional Properties (via PR Newswire)The Company Also Provides Update on CE Mark Submission Download image Logo. (PRNewsFoto/Cardium Therapeutics) SAN DIEGO, Aug. 5, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced that it has filed a new 510(k) submission for…
published: August 5, 2013 in: Clinical Studies/Trials, Regulatory, Wound Care